Business Wire

UMA

14.12.2021 11:02:09 CET | Business Wire | Press release

Share
Jabra and UMA Deliver Integrated Meeting Room Technology Solutions to Transform the Workplace

Jabra and UMA have partnered to deliver innovative video conferencing and meeting room solutions, enabling Jabra devices to be managed seamlessly from one place on the UMA dashboard with real-time analytics. With Jabra PanaCast intelligent video conferencing cameras, users can manage meeting room occupancy levels and control room occupancy levels from a desktop, smartphone or meeting room display panel to optimise the use of office space.

The Jabra PanaCast and PanaCast 50’s unique 180-degree field-of-view covers the whole room and generates anonymous room occupancy data. This feeds real-time information into the UMA dashboard, providing insights and analytics. UMA automatically makes a meeting room available to book in the event of a no-show. Rooms can also be auto-booked by simply walking in.

With the shift towards hybrid-working, companies are reviewing their technology investments and office space-utilisation. UMA enables users to manage meeting-room and desk utilisation and device management of audio-visual devices, all from a single pane of glass. Organisations are now able to optimise their facilities and technology infrastructure to create an efficient and safe workplace, compliant with Covid Winter-Plan guidelines.

The combined value-proposition of UMA and Jabra allows customers to realise an improved return on their technology investments through business intelligence and simpler mechanisms to support and maintain their meeting room technology. Users can check Jabra device status, remotely diagnose and fix issues, and push software updates.

Nigel Dunn, Managing Director, EMEA North at Jabra says, “We are thrilled to be teaming up with UMA to deliver a new standard in meeting room solutions for hybrid working. Jabra PanaCast’s data-driven insights and analytics gives a real-time view of how the workplace is being used, enabling companies to improve efficiency and maximise their real estate. It’s now time to start thinking about future-proofing offices and taking conferencing and the meeting booking experience to the next level.”

Nathan Rogers, Head of Channel, UMA says, “I’m looking forward to continuing to build a strong partnership with Jabra. The UMA and Jabra integration will deliver meaningful insights to businesses ensuring they understand how their real estate is being used. UMA delivers a simplified user experience to enable the booking of meeting spaces, and when partnered with the Jabra PanaCast the business has enhanced analytical data at their fingertips. Jabra’s audio experience and smart UC technology working in coalition with our Workplace Software will deliver a game changing advantage to users.”

Working in partnership with our mutual UK and European distributors means the reseller and Integrator customers will get a cohesive approach.”

The Jabra PanaCast is supported on UMA’s platform today, with PanaCast 50 to follow in early 2022.

For more information, please visit: https://www.jabra.co.uk/Business/for-your-platform/uma

About Jabra

Jabra is a world leading brand in audio, video, and collaboration solutions – engineered to empower consumers and businesses. Proudly part of the GN Group, we are committed to letting people hear more, do more, and be more than they ever thought possible. Jabra engineering excellence leads the way, building on 150 years of pioneering work within the GN Group.

This allows us to create integrated tools for contact centres, offices, and collaboration that help professionals work more productively from anywhere; and true wireless headphones and earbuds that let consumers better enjoy calls, music, and media. The GN Group, founded in 1869, operates in 100 countries and delivers innovation, reliability, and ease of use. GN employs 6,500 people and in 2020 reported annual revenue of DKK 13.4bn. The Jabra brand accounts for approx. DKK 8.7bn and employs 1,900 people. GN makes life sound better and is Nasdaq Copenhagen listed. www.jabra.com

About UMA

UMA is an innovative workplace software-as-a-service platform, connecting internet-of-things, audio, video, and collaboration technology and digitising the workplace environment.

Driven by a passion to improve technology user experiences in the workplace UMA enables you to book and manage resources and optimise space and environmental conditions, adapting to the changing needs of the workforce.

UMA was founded in Halifax, Yorkshire, UK and delivers solutions to enterprise and SME customers from all industry verticals across the world.

Find out more and get started with a free trial of UMA at www.askuma.ai

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 11:30:00 CET | Press release

Second limited-edition WHOOP x SR_A collection brings “performance for life” to new WHOOP bands, technical apparel, outerwear, and accessories designed for movement across city and rural environments. WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural wo

Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 11:28:00 CET | Press release

Oral-B iO helps you avoid new tooth and gum issues—and if you have existing gum problems, it can resolve them quicker than a manual toothbrush. Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums

Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release

Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates

Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye